Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Jul 5 2018

Full Issue

HPV Test More Sensitive To Precancerous Cell Changes Than Widely Used Pap Smear, Study Finds

Most medical groups have been recommending both tests, but now some experts suggest the HPV test alone is sufficient. Almost all cervical cancers are caused by the human papillomavirus.

The Washington Post: HPV Test Is Better Than Pap Smear At Detecting Precancerous Cervical Changes, Study Says

A test for HPV detects precancerous changes of the cervix earlier and more accurately than the Pap smear, according to a large clinical trial published Tuesday. The randomized, controlled study — the kind of trial considered the “gold standard” of research — showed that the human papillomavirus test is more sensitive than the Pap smear, a widely used test that has been a standard part of women's preventive health care for decades but has drawbacks. (McGinley, 7/3)

NPR: Study: HPV Tests Outperform Pap Smears In Testing For Cervical Cancer

The FDA in 2014 approved the first HPV test, which tests vaginal and cervical secretions (which can be gathered with a swab) for the presence of HPV. The new study, called the HPV FOCAL trial, compared the HPV test with traditional Pap smear screening among 19,000 Canadian women over four years. It adds to a body of research suggesting that HPV testing might be more accurate. "In our world this study is going to be a pretty big deal, in a good way," says Dr. Kathleen Schmeler, a gynecologic oncologist at the University of Texas MD Anderson Cancer Center. (Watson, 7/3)

And in other women's health news —

Kansas City Star: Debate Over Abortion Rights Roils Missouri Democrats

Annie Rice shocked a room full of Democrats over the weekend when she suggested the state party should amend its platform to include a provision permitting its members to support a right-to-work law in Missouri. “Everyone was staring at me like I had three heads for suggesting this,” said Rice, an alderwoman in St. Louis and a member of the committee that helped draft the platform. Rice had no intention of actually amending the platform. She vehemently opposes right-to-work and withdrew the amendment before any vote was taken. (Hancock, 7/5)

Dallas Morning News: Planned Parenthood Of Greater Texas Now Offers HIV-Prevention Drugs, Hormone Therapy  

Planned Parenthood of Greater Texas wants Texans to know that all of its health centers have started offering drugs critical to reducing the spread of HIV. These medications, known as PrEP, or pre-exposure prophylaxis, and PEP, or post-exposure prophylaxis, reduce a person’s chances of contracting the AIDS virus. The service comes as public health experts are still searching for solutions to improve access to the medication among groups that have historically lacked HIV-related care. (Perez and Lambert, 7/4)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF